Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma. [electronic resource]
Producer: 20160915Description: 5222-34 p. digitalISSN:- 1557-3265
- Adult
- Antineoplastic Agents -- pharmacology
- Apoptosis Regulatory Proteins -- genetics
- Bcl-2-Like Protein 11
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Fusion Proteins, bcr-abl -- genetics
- Gene Expression Regulation, Neoplastic -- drug effects
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- diagnosis
- MAP Kinase Signaling System -- drug effects
- Male
- Melanoma -- diagnosis
- Membrane Proteins -- genetics
- Mutation
- Neoplasm Metastasis
- Neoplasms, Multiple Primary -- diagnosis
- Neoplasms, Unknown Primary
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins -- genetics
- Proto-Oncogene Proteins B-raf -- antagonists & inhibitors
- Treatment Outcome
No physical items for this record
Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.